Summary of diagnoses and International Prognostic Scoring System (IPSS) risk groups, reduced-intensity and standard conditioning
Median age, y (range) . | Reduced-intensity (n = 60) . | Standard conditioning (n = 61) . | ||||
---|---|---|---|---|---|---|
Sibling 51 (27-70) . | VUD 49 (21-58) . | Total 50 (21-70) . | Sibling 37 (17-59) . | VUD 28 (18-43) . | Total 33 (17-59) . | |
Myelodysplastic syndrome | 17 | 31 | 48 | 22 | 14 | 36 |
RA/RC | 3 | 11 | 14 | 10 | 8 | 18 |
RAEB-I | 6 | 4 | 10 | 2 | 1 | 3 |
RAEB-II | 3 | 3 | 6 | 3 | 1 | 4 |
RAEB-t/TLD-AML | 4 | 8 | 12 | 6 | 4 | 10 |
CMML | 1 | 5 | 6 | 1 | 0 | 1 |
De novo acute myeloid leukemia | 6 | 6 | 12 | 17 | 8 | 25 |
IPSS risk groups | ||||||
High* | 16 | 18 | 34 | 26 | 12 | 38 |
Intermediate-2 | 4 | 10 | 14 | 6 | 3 | 9 |
Intermediate-1 | 3 | 9 | 12 | 5 | 7 | 12 |
Low | 0 | 0 | 0 | 2 | 0 | 2 |
Median age, y (range) . | Reduced-intensity (n = 60) . | Standard conditioning (n = 61) . | ||||
---|---|---|---|---|---|---|
Sibling 51 (27-70) . | VUD 49 (21-58) . | Total 50 (21-70) . | Sibling 37 (17-59) . | VUD 28 (18-43) . | Total 33 (17-59) . | |
Myelodysplastic syndrome | 17 | 31 | 48 | 22 | 14 | 36 |
RA/RC | 3 | 11 | 14 | 10 | 8 | 18 |
RAEB-I | 6 | 4 | 10 | 2 | 1 | 3 |
RAEB-II | 3 | 3 | 6 | 3 | 1 | 4 |
RAEB-t/TLD-AML | 4 | 8 | 12 | 6 | 4 | 10 |
CMML | 1 | 5 | 6 | 1 | 0 | 1 |
De novo acute myeloid leukemia | 6 | 6 | 12 | 17 | 8 | 25 |
IPSS risk groups | ||||||
High* | 16 | 18 | 34 | 26 | 12 | 38 |
Intermediate-2 | 4 | 10 | 14 | 6 | 3 | 9 |
Intermediate-1 | 3 | 9 | 12 | 5 | 7 | 12 |
Low | 0 | 0 | 0 | 2 | 0 | 2 |
RA indicates refractory anemia; RC, refractory cytopenias; RAEB, refractory anemia with excess blasts; TLD-AML, tri-lineage dysplasia acute myeloid leukemia; and CMML, chronic myelomonocytic leukemia.
Although the IPSS is not used in AML, for the purpose of this analysis, all AMLs have been classified as “high” risk.